| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P2093 | author name string | Rocio Lopez | |
| Marco A Costa | |||
| Ashish Atreja | |||
| Mazen Albeldawi | |||
| Anthony Post | |||
| Surabhi Madhwal | |||
| P2860 | cites work | Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events | Q44348839 |
| Is there disparity between risk and incidence of cardiovascular disease after liver transplant? | Q44728976 | ||
| Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. | Q45931278 | ||
| Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials | Q46668964 | ||
| Analysis of causes of death in liver transplant recipients who survived more than 3 years | Q46778404 | ||
| Validation of cardiovascular risk scores in a liver transplant population | Q46961016 | ||
| Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. | Q51372794 | ||
| Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. | Q51466759 | ||
| Metabolic syndrome after kidney transplantation | Q56995060 | ||
| Conducting Meta-Analyses in R with the metafor Package | Q58423162 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Clinical practice. Aspirin for primary prevention of coronary events | Q28192974 | ||
| Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition | Q29615691 | ||
| The hazards of scoring the quality of clinical trials for meta-analysis | Q29619369 | ||
| Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines | Q29619614 | ||
| Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association | Q34469606 | ||
| Cardiovascular morbidity and mortality after orthotopic liver transplantation | Q34581979 | ||
| Cardiovascular toxicities of immunosuppressive agents | Q34976738 | ||
| Statins in solid organ transplantation: is there an immunosuppressive effect? | Q35804356 | ||
| New-onset diabetes after transplantation: a review of recent literature | Q37526175 | ||
| Optimal utilization of extended hepatic grafts | Q37603098 | ||
| Posttransplant metabolic syndrome: an epidemic waiting to happen | Q37638639 | ||
| Metabolic syndrome and liver transplantation: a review and guide to management | Q37745416 | ||
| A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group | Q41439111 | ||
| Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infec | Q43190994 | ||
| Clinical diagnosis of metabolic syndrome: predicting new-onset diabetes, coronary heart disease, and allograft failure late after kidney transplant | Q43749603 | ||
| P433 | issue | 10 | |
| P921 | main subject | cardiovascular disease | Q389735 |
| meta-analysis | Q815382 | ||
| liver transplantation | Q1368191 | ||
| risk factor | Q1475848 | ||
| P304 | page(s) | 1140-1146 | |
| P577 | publication date | 2012-10-01 | |
| P1433 | published in | Liver Transplantation | Q15730498 |
| P1476 | title | Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies | |
| P478 | volume | 18 |
| Q37031745 | A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma |
| Q88581886 | Application of the Revised Cardiac Risk Index to the Model for End-Stage Liver Disease Score Improves the Prediction of Cardiac Events in Patients Undergoing Liver Transplantation |
| Q92824585 | Cardiovascular and Metabolic Consequences of Liver Transplantation: A Review |
| Q33716191 | Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do |
| Q38103630 | Cardiovascular risk, atherosclerosis and metabolic syndrome after liver transplantation: a mini review |
| Q49812544 | Changes in dietary patterns and body composition within 12 months of liver transplantation. |
| Q26738307 | Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implications |
| Q45960797 | Clinical Food Addiction Is Not Associated with Development of Metabolic Complications in Liver Transplant Recipients. |
| Q37284598 | Combined liver transplantation and sleeve gastrectomy for end-stage liver disease in a bariatric patient: First European case-report |
| Q45010550 | Evolution of serum atherogenic risk in liver transplant recipients: Role of lipoproteins and metabolic and inflammatory markers |
| Q36923179 | Factors Affecting Exercise Test Performance in Patients After Liver Transplantation |
| Q40233415 | Hepatic artery stenosis after liver transplantation: is endovascular treatment always necessary? |
| Q38089361 | Hypercoagulability as a contributor to thrombotic complications in the liver transplant recipient. |
| Q90601583 | Incidence of Recurrent NASH-Related Allograft Cirrhosis |
| Q90084905 | Is everolimus linked to metabolic syndrome in liver transplant recipients? |
| Q26750468 | Lipids in liver transplant recipients |
| Q46706110 | Liver Transplantation in Patients With Cardiac Disease |
| Q39295671 | Liver transplantation: post-transplant management |
| Q38186718 | Long term outcomes after pediatric liver transplantation |
| Q38270960 | Long-term management after liver transplantation: primary care physician versus transplant hospital. |
| Q51008260 | Long-term survivors after pediatric liver transplatation are at increased risk for development of cardiovascular disease events: analysis of 30 cases |
| Q36492663 | Major influence of renal function on hyperlipidemia after living donor liver transplantation |
| Q26770033 | Management of immunosuppressant agents following liver transplantation: Less is more |
| Q92458712 | Management of metabolic syndrome and cardiovascular risk after liver transplantation |
| Q37421526 | Medical Management of Metabolic Complications of Liver Transplant Recipients |
| Q40434270 | Metabolic Syndrome After Liver Transplantation: Five-Year Prevalence and Risk Factors |
| Q28082243 | Metabolic and cardiovascular complications in the liver transplant recipient |
| Q28073134 | Metabolic complications in liver transplant recipients |
| Q35924990 | Metabolic syndrome after a liver transplantation in an Asian population. |
| Q33660027 | Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? |
| Q47880583 | New Definition Criteria of Myocardial Dysfunction in Patients with Liver Cirrhosis: A Speckle Tracking and Tissue Doppler Imaging Study |
| Q39061276 | Overweight, central obesity, and cardiometabolic risk factors in pediatric liver transplantation. |
| Q97425388 | Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation |
| Q93344346 | Pre- and post-transplant factors associated with body weight parameters after liver transplantation - A systematic review and meta-analysis |
| Q39304271 | Risk factors for metabolic syndrome after liver transplantation: A systematic review and meta-analysis. |
| Q46142761 | Subclinical Atherosclerosis in Pediatric Liver Transplant Recipients: Carotid and Aorta Intima-Media Thickness and Their Predictors |
| Q35060274 | Weight gain, overweight and obesity in solid organ transplantation--a study protocol for a systematic literature review. |
| Q38250176 | mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern? |
Search more.